U.S. markets open in 4 hours 38 minutes

Cyclacel Pharmaceuticals, Inc. (CYCCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.77-0.93 (-12.08%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.70
Bid0.00 x 1000
Ask7.75 x 800
Day's Range7.73 - 7.73
52 Week Range5.17 - 11.17
Avg. Volume68
Market Cap12.873M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-2.05
Earnings DateMay 12, 2020
Forward Dividend & Yield0.60 (8.86%)
Ex-Dividend DateOct 14, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYCCP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyclacel Pharmaceuticals, Inc.
    Technical Assessment: Bearish in the Intermediate-TermCommodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Benzinga

    Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients

    Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities. Fifteen patients with advanced solid tumors and lymphomas were treated with oral fadraciclib at all five doses. In the first oral treatment cycle with fadraciclib, a cutaneous T cell lymphoma patient achieved partial response (PR). A patient

  • GlobeNewswire

    Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

    - Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of Target Engagement for CDK2 and CDK9 - - Early Anticancer Activity, Including Partial Response and Stable Disease with Tumor Shrinkage,Observed in Patients with Endometrial Cancer, Pancreatic Cancer and T Cell Lymphoma - - R&D Day Planned for Fall 2022 - BERKELEY HEIGHTS, N.J., June 30, 2022 (GLOBE NEWSWIR

  • GlobeNewswire

    Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors

    BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders. "We are very pleased to welcome Ken to our Board of Directors,” said Ch